Sevigny, Jeff MD; Suhy, Joyce PhD; Chiao, Ping PhD; Chen, Tianle PhD; Klein, Gregory PhD; Purcell, Derk MD; Oh, Joonmi PhD; Verma, Ajay MD, PhD; Sampat, Mehul PhD; Barakos, Jerome MD
*Biogen, Cambridge, MA
†Bioclinica Inc., Newark
‡California Pacific Medical Center
§Department of Radiology, University of California San Francisco, San Francisco, CA
Supported by Biogen. Editorial support was provided by Annette Smith, PhD of Complete Medical Communications (Macclesfield, Cheshire, UK) and was funded by Biogen.
J.S. is a former employee of Biogen. P.C., T.C., and A.V. are employees of Biogen and P.C. holds stocks/stock options in Biogen. J.S., G.K., J.O., and M.S. are employees of BioClinica Inc. D.P. and J.B. are contractors with BioClinica Inc.
Reprints: Ping Chiao, PhD, Biogen, 255 Binney Street, Cambridge, MA 02142 (e-mail: [email protected]).
Received July 17, 2015
Accepted January 18, 2016
doi: 10.1097/WAD.0000000000000144
Erratum
In the article that appeared on page 1 of the January-March 2016 issue, an error appeared at the end of the first column of page 4. The corrected sentence should read:
Overall, based on visual reads, PET amyloid positivity was highest among mild AD ApoE E4 carriers (90%), followed by prodromal AD ApoE E4 carriers (71%), mild AD noncarriers (58%), and prodromal AD noncarriers (31%).
Alzheimer Disease & Associated Disorders.
30(2):193,
April-June 2016.
